Innovation

Sustained release bionanocomposites, a process for producing the same and use thereof.

Laser Consult Ltd.
posted on 10/17/2011

Our partner, a Hungarian University has developed a novel invention which relates to a sustained release, core-shell structure, cytokine-containing bionanocomposite, a process for preparation thereof and use of said core-shell bionanocomposite in the preparation of a sustained release pharmaceutical composition. The client is interested in finding partners for joint R & D.

Suggested Uses

Preparation of a sustained release pharmaceutical composition.

Advantages

The present solution is suitable: •to control the particle size on demand, •to prevent aggregation (colloid destabilization), •to ensure controlled release kinetics (sustained release), •to prevent denaturation of the encapsulated protein and to preserve biological activity.

Innovation Details
 

Detailed Description

Innovation of the product The present invention is directed to a nanocomposite providing sustained release of bioactive proteins which comprises: • a charge-carrying, bioactive protein core, precipitated reversibly in an ionic mechanism and • polyelectrolyte shell around the said core consisting of two oppositely charged polyelectrolytes, forming 3 to 5 layers, where one of the polyelectrolytes has pH-dependent charges while the other polyelectrolyte has permanent, pH-independent charge. Further, the present invention is directed to a procedure for the preparation of said nanocomposite wherein: • a biocative protein or a protein mixture containing at least one bioactive protein, • the precipitated protein of positive charge or of negative charge is separated by centrifugation, • a solution of a first polyelectrolyte that is oppositely charged relative to the protein is added to the above protein sediment while mixing at a pH adjusted by a buffer to the pH of the precipitated protein, • the polyelectrolyte-coated nanocomposite particles charged oppositely relative to the precipitated protein core are separated by centrifugation and optionally washed with buffer solution, • a solution of a second polyelectrolyte, charged oppositely relative to the first polyelectrolyte is added to the sediment at the same pH adjusted by buffer, • the two-polyelectrolyte-coated nanocomposite particles having similar charge as the protein core are separated by centrifugation and optionally washed with buffer, • sediment of the core-shell nanocomposite containing 3 to 5 coating layers as desired on the primary protein nanoparticle is freeze-dried. In further aspects the present invention is directed: • to a sustained release drug formulation which comprises a nanocomposite according to the invention and optionally other bioactive agent(s) and pharmaceutically acceptable inert carrier(s) and/or other excipient(s), • to the use of said nanocomposite in the preparation of a sustained release drug formulation. Further informations about the presented technology The technology have been developing with interferon as core protein and regarding the mentioned type of core protein the next step is to increase the level of the technology to industrial size. If the inquiring partner would like to use different type of molecule as core protein our partner, a Hungarian University (the inventor of the technology) possesses a well equipped lab and a well qualified expert team to help them optimize the technology for the requirements.

File Number: MED-LC-015-TO 


IP Protection

Patent Number(s): PCT/HU2008/000028

License Online

This innovation currently is not available for online licensing. Please contact Dr. Peter Mogyorosi at Laser Consult Ltd. for more information.

Request more info via email request more info
People

Case Manager:

Dr. Peter Mogyorosi Dr. Peter Mogyorosi

Innovations (0)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

12,874 members 17,311 innovations 176 organizations

Browse

William Garner, M.D., MPH - CEO of Urigen, N.A., Inc.

"The iBridge Network provides an important additional pathway for entrepreneurs to access university innovations that may otherwise have been lost. The transparency of this pathway between entrepreneurs..."  read more...